Ardelyx delivered an outstanding second quarter in 2025, generating $97.7 million in total revenue, a 33% increase year-over-year. Both commercial products, IBSRELA and XPHOZAH, showed significant results, with IBSRELA recording its highest revenue quarter at $65.0 million and XPHOZAH generating $25.0 million. The company ended the quarter with $238.5 million in cash, cash equivalents, and investments, and raised its 2025 IBSRELA net sales revenue expectations.
Total revenue for Q2 2025 reached $97.7 million, marking a 33% increase compared to Q2 2024.
IBSRELA net sales revenue was $65.0 million, reflecting an 84% year-over-year growth.
XPHOZAH net sales revenue was $25.0 million, showing a 7% quarter-over-quarter increase.
The company's cash, cash equivalents, and investments stood at $238.5 million at the end of Q2 2025.
Ardelyx has raised its full-year 2025 IBSRELA net sales revenue expectations and remains focused on commercial execution and bringing medicines to patients.
Analyze how earnings announcements historically affect stock price performance